Developing tomorrow’s antipsychotics: the need for a more personalised approach

  title={Developing tomorrow’s antipsychotics: the need for a more personalised approach},
  author={R. Hunter},
  journal={Advances in Psychiatric Treatment},
  • R. Hunter
  • Published 2014
  • Medicine
  • Advances in Psychiatric Treatment
  • There has been little pharmacological advance in the treatment of schizophrenia since the introduction of chlorpromazine in the 1950s. This may be set to change as recent advances in molecular biology offer the prospect of a better understanding of the pathophysiology of the disorder and allow investigation of the complex interplay of genetic and environmental risk factors. In this review I discuss future approaches to antipsychotic drug development, highlighting the need to better define… CONTINUE READING
    3 Citations


    The pipeline and future of drug development in schizophrenia
    • 164
    • PDF
    Antipsychotic treatment in schizophrenia: atypical options and NICE guidance.
    • A. Mortimer
    • Medicine
    • European psychiatry : the journal of the Association of European Psychiatrists
    • 2003
    • 19
    Role of DISC1 in neural development and schizophrenia
    • 95
    Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
    • J. Coyle
    • Medicine
    • Cellular and Molecular Neurobiology
    • 2006
    • 829
    Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    • 4,788
    • PDF